Braftovi

• Braftovi is a prescription medication, specifically a kinase inhibitor, used in targeted cancer therapy.
• It is primarily indicated for melanoma and metastatic colorectal cancer with a *BRAF* V600E or V600K mutation.
• The medication works by blocking the activity of the mutated BRAF protein, often in combination with Mektovi (binimetinib).
• Patients must undergo genetic testing to confirm the presence of the specific *BRAF* mutation before starting treatment.
• Common side effects include fatigue, nausea, and skin reactions, and patients should discuss all potential effects with their healthcare provider.

What is Braftovi (Encorafenib)?

Braftovi refers to encorafenib, an oral prescription medication classified as a kinase inhibitor. It is a targeted therapy designed to specifically interfere with the growth and spread of cancer cells by blocking the activity of certain enzymes. This medication is part of a class of drugs known as BRAF inhibitors, which are crucial for treating cancers driven by mutations in the *BRAF* gene. The presence of a *BRAF* mutation is identified through specific diagnostic tests, which are essential before initiating treatment with Braftovi.

What is Braftovi Used For?

Braftovi is used for treating specific types of cancer that harbor a *BRAF* V600E or V600K mutation. Its primary indications include unresectable or metastatic melanoma and metastatic colorectal cancer (mCRC). For melanoma, it is typically used in combination with binimetinib (Mektovi). For mCRC, it is also used in combination with binimetinib and cetuximab. These mutations lead to overactive BRAF proteins, which promote uncontrolled cell growth and survival. Targeted therapies like Braftovi are designed to specifically inhibit these mutated proteins, thereby slowing or stopping cancer progression.

The importance of identifying the *BRAF* mutation cannot be overstated, as it determines a patient’s eligibility for this specific treatment. According to various oncology research studies, approximately 40-50% of melanomas carry a *BRAF* mutation, making it a significant target for therapy. Similarly, a subset of metastatic colorectal cancers also presents with *BRAF* mutations, for which Braftovi offers a targeted treatment option.

How Does Braftovi Work, Side Effects, and Patient Information

The mechanism of action for how does Braftovi work involves its role as a kinase inhibitor, specifically targeting the BRAF protein. In cancer cells with *BRAF* V600 mutations, this protein becomes overactive, leading to a cascade of signals that drive cell proliferation and survival. Braftovi selectively binds to and inhibits the activity of this mutated BRAF protein. When used in combination with binimetinib (Mektovi), which inhibits MEK (a protein downstream of BRAF in the signaling pathway), the dual blockade provides a more comprehensive approach to disrupting the cancer’s growth signals, often leading to improved outcomes compared to single-agent therapy.

Like all medications, Braftovi can cause Braftovi side effects, which can range from mild to severe. It is crucial for patients to be aware of these and to report any new or worsening symptoms to their healthcare provider promptly. Common side effects often include:

• Fatigue
• Nausea, vomiting, and diarrhea
• Abdominal pain
• Skin reactions (e.g., rash, dry skin, sensitivity to sun)
• Muscle and joint pain
• Headache
• Hair loss
• Vision problems

More serious side effects can include new primary skin cancers (cutaneous squamous cell carcinoma), heart problems, eye problems, liver problems, and severe skin reactions. Regular monitoring by a healthcare professional is essential to manage potential side effects.

Comprehensive Braftovi patient information is vital for individuals undergoing this treatment. Patients should adhere strictly to their prescribed dosage and administration schedule, typically taking the capsules orally once daily, with or without food. It is important not to crush, chew, or open the capsules. Patients should inform their doctor about all other medications, supplements, and herbal products they are taking, as these can interact with Braftovi. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose, as Braftovi can harm a developing fetus. Regular follow-up appointments, blood tests, and skin examinations are necessary to monitor treatment effectiveness and manage potential adverse reactions, ensuring the best possible care throughout the therapy.